1. Volume 60, Issue 6, Pages 1251-1257 (December 2011)
Gemcitabine or Gemcitabine Plus Oxaliplatin in the First-Line Treatment of Patients With Advanced Transitional Cell Carcinoma of the Urothelium Unfit for Cisplatin-Based Chemotherapy: A Randomized Phase 2 Study of the French Genitourinary Tumor Group (GETUG V01) 
Stéphane Culine, Aude Fléchon, Aline Guillot, Sylvestre Le Moulec, Damien Pouessel, Frédéric Rolland, Alain Ravaud, Nadine Houédé, Laurent Mignot, Florence Joly, Stéphane Oudard, Sophie Gourgou 
European Urology 
Volume 60, Issue 6, Pages (December 2011)
DOI: /j.eururo
Copyright © 2011 European Association of Urology Terms and Conditions

2. Fig. 1 Consolidated Standards of Reporting Trials diagram.
GEM=gemcitabine; GEMOX=gemcitabine plus oxaliplatin.
European Urology  , DOI: ( /j.eururo )
Copyright © 2011 European Association of Urology Terms and Conditions

3. Fig. 2 Overall survival according to treatments.
GEM=gemcitabine; GEMOX=gemcitabine plus oxaliplatin.
European Urology  , DOI: ( /j.eururo )
Copyright © 2011 European Association of Urology Terms and Conditions

4. Fig. 3 Overall survival according to stratification factors.
GFR=glomerular filtration rate; PS=performance status.
European Urology  , DOI: ( /j.eururo )
Copyright © 2011 European Association of Urology Terms and Conditions